Despite decades of intensive research, there are still no effective treatments or efficacious drugs to cure or even slow the progression of Alzheimer disease (AD). The same is true of the other dementias that afflict the elderly. In AD, data indicate that the peptide Aβ is the key molecule involved in initiating the disease.
149,150 Aβ is very prone to aggregate and most is present in the brains of AD patients as extracellular amyloid plaque. When AD plaque was analyzed, the vast majority was found to have been modified in the same manner as described above for proteins in aged lenses.
151,152 For example, Asp residues were present as isoAsp,
149 a large proportion of Aβ was cross-linked,
153 and
d-Ser was found at several sites,
154 as was cleavage of N-terminal to Ser. In addition, the majority of plaque was found to be composed of truncated (laddered) versions. These various modifications could be reproduced by incubating sequences of the Aβ peptide, showing that these products were the result of spontaneous reactions.
62 Amyloid plaque is thus highly heterogeneous, and it remains to be determined how these multitudinous, closely related forms interact to cause the disease and to what extent animal models will play a role in the elucidation of AD.
155